Open Access Gold as soon as Publ. Version/Full Text is submitted to ZB.
Profile identification of disease-associated humoral antigens using AMIDA, a novel proteomics-based technology.
Cell. Mol. Life Sci. 61, 1198-1207 (2004)
We describe AMIDA (autoantibody-mediated identification of antigens), a novel target identification technology based on the immunoprecipitation of disease-specific antigens by autologous serum antibodies followed by two-dimensional electrophoretic separation, and their identification via mass spectrometry. Twenty-seven potential carcinoma antigens were identified including proteins of hitherto unknown function. Validation of one of the identified antigens, cytokeratin 8, revealed its de novo expression in hyperplastic tissue, gradual overexpression with increasing malignancy, and ectopic localization on the cell surface. Furthermore, a strong prevalence of CK8-specific antibodies occurred in the serum of cancer patients already at early disease stages. In situ hybridization for one marker of unknown function, KIAA1273/TOB3, demonstrated its strong overexpression in head and neck carcinomas, thus making it a likely tumor antigen candidate. Eventually, AMIDA could foster significant improvements for the diagnosis and therapy of human diseases eliciting a humoral immune response, and allows for the rapid identification of new target molecules.
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Scientific Article
Keywords
Amida ; Ck8 ; Hnscc ; Humoral Antigens ; Kiaa1273/tob3
ISSN (print) / ISBN
1420-682X
e-ISSN
1420-9071
Quellenangaben
Volume: 61,
Issue: 10,
Pages: 1198-1207
Publisher
Birkhäuser
Reviewing status
Peer reviewed
Institute(s)
Research Unit Gene Vector (AGV)